Literature DB >> 6813351

Serotypes of Pseudomonas aeruginosa in clinical specimens in relation to antibiotic susceptibility.

N J Legakis, M Aliferopoulou, J Papavassiliou, M Papapetropoulou.   

Abstract

Ninety-eight hospital strains of Pseudomonas aeruginosa isolated from six different hospitals in Athens were serotyped by a slide agglutination test with unabsorbed commercial antisera. Serotypes O6, O11, O12, and "pool E" strains (strains that agglutinated only in pool E, which contained antisera against O2, O5, O15, and O16 antigens, but did not agglutinate in the individual antisera) predominated, accounting for more than 62% of all isolates tested. In respect to serotypes, (i) there was no apparent correlation with hospital of origin, (ii) most strains of serotypes O6 and O11 were sensitive to gentamicin and carbenicillin (iii) most strains of pool E were from urine and were resistant to these drugs, (iv) all 9 strains of serotype O12 tested were resistant to carbenicillin and all 5 strains tested hydrolyzed this drug, and (v) 24 of 25 strains of pool E were resistant to carbenicillin but only 2 of 17 strains hydrolyzed it.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6813351      PMCID: PMC272389          DOI: 10.1128/jcm.16.3.458-463.1982

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  33 in total

1.  Epidemiology of nosocomial infection due to Gram-negative bacilli: aspects relevant to development and use of vaccines.

Authors:  W E Stamm; S M Martin; J V Bennett
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

2.  Preparation of typing antisera specific for O antigens of Pseudomonas aeruginosa.

Authors:  N H Duncan; N A Hinton; J L Penner; I B Duncan
Journal:  J Clin Microbiol       Date:  1976-08       Impact factor: 5.948

3.  The relationship between the O-antigenic lipopolysaccharides and serological specificity in strains of Pseudomonas aeruginosa of different O-serotypes.

Authors:  I R Chester; P M Meadow; T L Pitt
Journal:  J Gen Microbiol       Date:  1973-10

4.  Pseudomonas aeruginosa resistant to carbenicillin and gentamicin. Epidemiologic and clinical aspects in a cancer center.

Authors:  W H Greene; M Moody; S Schimpff; V M Young; P H Wiernik
Journal:  Ann Intern Med       Date:  1973-11       Impact factor: 25.391

5.  Phage typing of Pseudomonas aeruginosa: clinical and epidemiologic considerations.

Authors:  R B Lindberg; R L Latta
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

6.  Nosocomial infections due to Pseudomonas.

Authors:  J V Bennett
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

7.  Serotyping of Pseudomonas aeruginosa.

Authors:  V M Young; M R Moody
Journal:  J Infect Dis       Date:  1974-11       Impact factor: 5.226

8.  In vitro susceptibility of gentamicin-resistant Enterobacteriaceae and Pseudomonas aeruginosa to netilmicin and selected aminoglycoside antibiotics.

Authors:  R D Meyer; L L Draus; K A Pasieczinik
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

9.  Contamination of shellfish with strains of Pseudomonas aeruginosa and specific bacteriophages.

Authors:  F A Denis
Journal:  Can J Microbiol       Date:  1975-07       Impact factor: 2.419

10.  Serological typing of Pseudomonas aeruginosa: use of commercial antisera and live antigens.

Authors:  C D Brokopp; R Gomez-Lus; J J Farmer
Journal:  J Clin Microbiol       Date:  1977-06       Impact factor: 5.948

View more
  22 in total

1.  EVALUATION OF HOSPITAL ACQUIRED PSEUDOMONAS INFECTION IN PARAPLEGIC AND ORTHOPAEDIC CASES.

Authors:  K K Lahiri
Journal:  Med J Armed Forces India       Date:  2017-06-26

2.  In vitro activity of carumonam (RO 17-2301) and twelve other antimicrobials against clinical isolates of Pseudomonas aeruginosa.

Authors:  U Vurma-Rapp; F H Kayser
Journal:  Eur J Clin Microbiol       Date:  1986-06       Impact factor: 3.267

3.  Study of Pseudomonas aeruginosa serotype O12 isolates with a common antibiotic susceptibility pattern.

Authors:  A Talarmin; P Dubrous; P Gérome; Y Buisson
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-06       Impact factor: 3.267

4.  Antibiotic susceptibility of clinical isolates of Pseudomonas aeruginosa.

Authors:  C Cervantes-Vega; J Chavez; M G Rodriguez
Journal:  Antonie Van Leeuwenhoek       Date:  1986       Impact factor: 2.271

5.  Antibiograms, serotypes, and plasmid profiles of Pseudomonas aeruginosa associated with corneal ulcers and contact lens wear.

Authors:  M S Mayo; W L Cook; R L Schlitzer; M A Ward; L A Wilson; D G Ahearn
Journal:  J Clin Microbiol       Date:  1986-09       Impact factor: 5.948

6.  Importance of carbenicillin and gentamicin cross-resistant serotype 0:12 Pseudomonas aeruginosa in six Athens hospitals.

Authors:  N J Legakis; N Koukoubanis; K Malliara; D Michalitsianos; J Papavassiliou
Journal:  Eur J Clin Microbiol       Date:  1987-06       Impact factor: 3.267

7.  Reverse engineering antibiotic sensitivity in a multidrug-resistant Pseudomonas aeruginosa isolate.

Authors:  Julie M Struble; Ryan T Gill
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

Review 8.  Epidemiological typing of Pseudomonas aeruginosa.

Authors:  T L Pitt
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-04       Impact factor: 3.267

9.  Outer membrane alterations in multiresistant mutants of Pseudomonas aeruginosa selected by ciprofloxacin.

Authors:  N J Legakis; L S Tzouvelekis; A Makris; H Kotsifaki
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

10.  lfnA from Pseudomonas aeruginosa O12 and wbuX from Escherichia coli O145 encode membrane-associated proteins and are required for expression of 2,6-dideoxy-2-acetamidino-L-galactose in lipopolysaccharide O antigen.

Authors:  Jerry D King; Erin F Mulrooney; Evgeny Vinogradov; Bernd Kneidinger; Kristen Mead; Joseph S Lam
Journal:  J Bacteriol       Date:  2007-12-21       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.